{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:33:51Z","timestamp":1790984031914,"version":"4.1.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.cpcardiol.2007.01.004","type":"journal-article","created":{"date-parts":[[2007,5,7]],"date-time":"2007-05-07T14:23:16Z","timestamp":1178547796000},"page":"268-314","source":"Crossref","is-referenced-by-count":70,"title":["HDL Cholesterol: Physiology, Pathophysiology, and Management"],"prefix":"10.1016","volume":"32","author":[{"given":"Jeffrey J.","family":"Link","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Rohatgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"de Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2007.01.004_bib1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High-density lipoprotein as a protective factor against coronary heart disease: the Framingham study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein and cardiovascular disease","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"354","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib4","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1001\/jama.269.23.3002","article-title":"Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination surveys","volume":"269","author":"Johnson","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib5","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0002-9149(99)80761-9","article-title":"Distribution of lipids in 8500 men with coronary artery disease","volume":"75","author":"Rubins","year":"1995","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.cpcardiol.2007.01.004_bib6","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/01.CIR.0000012918.84068.43","article-title":"Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors","volume":"105","author":"Sacks","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib7","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1161\/01.ATV.17.4.786","article-title":"Plasma LDL and HDL subspecies are heterogeneous in particle content of tocopherols and oxygenated and hydrocarbon caretenoids","volume":"17","author":"Goulinet","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1194\/jlr.R400001-JLR200","article-title":"The oxidation hypothesis of atherogenesis; the role of oxidized phospholipids and HDL","volume":"45","author":"Navab","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib9","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJM198911093211907","article-title":"High-density lipoprotein\u2014the clinical implications of recent studies","volume":"321","author":"Gordon","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib10","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/01.ATV.0000057572.97137.DD","article-title":"Importance of different pathways of cellular cholesterol efflux","volume":"23","author":"Yancey","year":"2003","journal-title":"Arterioscler Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib11","doi-asserted-by":"crossref","first-page":"9774","DOI":"10.1073\/pnas.0403506101","article-title":"ATP-binding cassette transporters G1 and G4 mediate cellular efflux to high densiy lipoproteins","volume":"101","author":"Wang","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jacc.2005.09.042","article-title":"Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease","volume":"47","author":"Barter","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00041433-199908000-00007","article-title":"Scavenger receptor B1 and cholesterol trafficking","volume":"10","author":"Williams","year":"1999","journal-title":"Curr Opin Lipid"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib14","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1194\/jlr.M300511-JLR200","article-title":"Lipoprotein cholesteryl ester production, transfer and output in humans","volume":"45","author":"Schwartz","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0021-9150(87)90091-8","article-title":"Apolipoprotein A-I containing lipoproteins in coronary artery disease","volume":"68","author":"Puchois","year":"1987","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib16","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1161\/01.ATV.15.9.1412","article-title":"Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I\/A-II in native plasma","volume":"15","author":"Huang","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1161\/01.CIR.84.1.129","article-title":"HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction","volume":"84","author":"Fan","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib18","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/01.ATV.0000183727.90611.4f","article-title":"Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veterans affairs HDL intervention trial","volume":"25","author":"Asztalos","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1749-6632.1999.tb09231.x","article-title":"Oxidized LDL and atherogenesis","volume":"874","author":"Yla-Herttuala","year":"1999","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0005-2760(90)90314-N","article-title":"High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein","volume":"1044","author":"Parthasarathy","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.ATV.21.4.481","article-title":"HDL and the inflammatory response induced by LDL-derived oxidized phospholipids","volume":"21","author":"Navab","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib22","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/01.HYP.23.5.556","article-title":"Oxidized lipoproteins inhibit endothelium-dependent vasodilation","volume":"23","author":"Galle","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib23","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1006\/bbrc.1999.1278","article-title":"Reconstituted HDL containing apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice","volume":"264","author":"Dimayuga","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1161\/01.CIR.103.1.108","article-title":"Elevation of plasma high-density lipoprotein concentration reduces interleukin-1 induced expression of E-selectin in an in vivo model of acute inflammation","volume":"103","author":"Cockerill","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib26","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1161\/01.CIR.0000013424.28206.8F","article-title":"High-density lipoprotein restores endothelial function in hypercholesterolemic men","volume":"105","author":"Spieker","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib27","doi-asserted-by":"crossref","unstructured":"Nofer JR, Levkau B, Wolinska I, et al. Suppression of endothelial cell apoptosis by high-density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 276;34480-5.","DOI":"10.1074\/jbc.M103782200"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib28","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.jacc.2005.06.080","article-title":"High-density lipoprotein function: recent advances","volume":"46","author":"Ansell","year":"2005","journal-title":"JACC"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib29","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/89986","article-title":"High density lipoprotein binding to scavenger receptor-B1 activates endothelial nitric oxide synthase","volume":"7","author":"Yuhanna","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib30","doi-asserted-by":"crossref","first-page":"11058","DOI":"10.1074\/jbc.M110985200","article-title":"High density lipoprotein binding to scavenger receptor, Class B, type I activates endothelial nitric-oxide syntase in a ceramide-dependent manner","volume":"277","author":"Li","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib31","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI18004","article-title":"Suppression of endothelial cell apotosis by high-density lipoproteins (HDL) and HDL-associated lysosphingolipids","volume":"113","author":"Nofer","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib32","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1016\/S0021-9258(18)34477-6","article-title":"Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins","volume":"257","author":"Fleisher","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0021-9150(93)90115-B","article-title":"Stimulation of endothelin-1 release by low density and very low density lipoproteins in cultured human endothelial cells","volume":"101","author":"Horio","year":"1993","journal-title":"Atherosclerosis"},{"issue":"15","key":"10.1016\/j.cpcardiol.2007.01.004_bib34","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/0002-9149(91)90274-O","article-title":"Effects of high-density lipoprotein on acetylcholine-induced vasoreactivity","volume":"68","author":"Kuhn","year":"1991","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2007.01.004_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0049-3848(85)90116-1","article-title":"Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man","volume":"39","author":"Saku","year":"1985","journal-title":"Thromb Res"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib36","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/01.ATV.18.6.861","article-title":"HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate","volume":"18","author":"Nofer","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood.V64.2.365.365","article-title":"Interaction of plasma lipoproteins with human platelets","volume":"64","author":"Curtiss","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1172\/JCI5006","article-title":"High density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C","volume":"103","author":"Griffin","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib39","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults. (Adult Treatment Panel III). Final Report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib40","unstructured":"Assmann G, von Eckardstein A, Funke H, et al. High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations. Circulation 87;III28-34."},{"issue":"5","key":"10.1016\/j.cpcardiol.2007.01.004_bib41","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1172\/JCI3963","article-title":"Mapping a gene involved in regulating dietary cholesterol absorption.","volume":"102","author":"Patel","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev.ge.24.120190.001025","article-title":"The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein","volume":"24","author":"Hobbs","year":"1990","journal-title":"Annu Rev Genet"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib43","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/hmg\/ddh119","article-title":"Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol","volume":"13","author":"Knoblauch","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib44","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1210\/jc.2004-0305","article-title":"Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity","volume":"89","author":"Hansel","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib45","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/01.ATV.16.12.1509","article-title":"Impact of BMI on coronary heart disease risk factors in men and women; the Framingham Offspring Study","volume":"16","author":"Lamon-Fava","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib46","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","article-title":"Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis","volume":"56","author":"Datillo","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib47","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/01.ATV.18.3.441","article-title":"Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA study, protocol 1","volume":"18","author":"Ginsberg","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"s","key":"10.1016\/j.cpcardiol.2007.01.004_bib48","doi-asserted-by":"crossref","first-page":"41L","DOI":"10.1016\/S0002-9149(00)01469-7","article-title":"Nonpharmacologic management of low levels of high-density lipoprotein cholesterol","volume":"86","author":"Ginsberg","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib49","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJM199906243402501","article-title":"Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels","volume":"340","author":"Lichtenstein","year":"1999","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.cpcardiol.2007.01.004_bib50","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.161.18.2185","article-title":"The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease","volume":"161","author":"Harper","year":"2001","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2007.01.004_bib51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1172\/JCI111422","article-title":"Suppression by diets rich in fish oil of very low density lipoprotein production in man","volume":"74","author":"Nestel","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib52","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF02529870","article-title":"N-3 fatty acids and lipoproteins: comparison of results from human and animal studies","volume":"31","author":"Harris","year":"1996","journal-title":"Lipids"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib53","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0021-9150(00)00723-1","article-title":"Effect of dietary -3 fatty acids on high-density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus","volume":"157","author":"Frenais","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib54","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/01.CIR.81.4.1428","article-title":"What do muscles have to do with lipoproteins?","volume":"81","author":"Thompson","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib55","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0021-9150(97)00257-8","article-title":"Exercise training has little effect on HDL levels and metabolism in men with initially low HDL cholesterol","volume":"137","author":"Zmuda","year":"1998","journal-title":"Atherosclerosis"},{"issue":"suppl S","key":"10.1016\/j.cpcardiol.2007.01.004_bib56","first-page":"S123","article-title":"Role of exercise and weight loss in maximizing LDL cholesterol reduction","volume":"1","author":"Hardman","year":"1999","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib57","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1055\/s-2004-821160","article-title":"Evidence of major genes for plasma HDL, LDL cholesterol and triglyceride levels at baseline and in response to 20 weeks of endurance training: the HERITAGE Family Study","volume":"26","author":"An","year":"2005","journal-title":"Int J Sports Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib58","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1016\/0002-9343(92)90620-Q","article-title":"Smoking and cardiovascular disease","volume":"93","author":"Lakier","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0021-9150(78)90149-1","article-title":"Cigarette smoking and HDL cholesterol: the Framingham Offspring Study","volume":"30","author":"Garrison","year":"1978","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib60","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1136\/bmj.319.7224.1523","article-title":"Moderate alcohol intake and lower risk of coronary heart disease: a meta-analysis of effects on lipids and haemostatic factors","volume":"319","author":"Rimm","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1530-0277.1991.tb01857.x","article-title":"Effect of chronic ethanol feeding on high density lipoprotein subfractions in rats","volume":"15","author":"Lin","year":"1991","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"10.1016\/j.cpcardiol.2007.01.004_bib62","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00129784-200303010-00006","article-title":"Optimal therapy of low levels of high density lipoprotein-cholesterol","volume":"3","author":"Kashyap","year":"2003","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib63","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1161\/01.ATV.19.4.1051","article-title":"Niacin accelerates intracellular ApoB degredation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells","volume":"19","author":"Jin","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib64","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/01.ATV.17.10.2020","article-title":"Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells","volume":"17","author":"Jin","year":"1997","journal-title":"Arterioscler Thromb Basc Biol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib65","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib66","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib67","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib68","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-142-2-200501180-00008","article-title":"A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events","volume":"142","author":"Whitney","year":"2005","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.cpcardiol.2007.01.004_bib69","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"JACC"},{"issue":"12","key":"10.1016\/j.cpcardiol.2007.01.004_bib70","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0002-9149(03)00394-1","article-title":"Effects of extended-release niacin on lipoprotein subclass distribution","volume":"91","author":"Morgan","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib71","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/archinte.154.14.1557","article-title":"Nicotinic acid as a lipoprotein-altering agent","volume":"154","author":"Probstfield","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib72","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/archinte.154.14.1586","article-title":"Comparative effects of lovastatin and niacin in primary hypercholesterolemia","volume":"154","author":"Illingworth","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib73","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/83348","article-title":"PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway","volume":"7","author":"Chawla","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib75","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib76","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archinte.160.8.1177","article-title":"Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia","volume":"160","author":"Guyton","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib77","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"9B","key":"10.1016\/j.cpcardiol.2007.01.004_bib78","first-page":"30F","article-title":"Role of fibrates in the management of hypertriglyceridemia","volume":"83","author":"McKenney","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib79","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0021-9150(99)00053-2","article-title":"Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease","volume":"144","author":"Schaefer","year":"1999","journal-title":"Atherosclerosis"},{"issue":"suppl C","key":"10.1016\/j.cpcardiol.2007.01.004_bib80","doi-asserted-by":"crossref","first-page":"C58","DOI":"10.1016\/j.ehjsup.2004.04.002","article-title":"Are the effects of statins on HDL-cholesterol clinically relevant?","volume":"6","author":"Chapman","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib81","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(00)04053-8","article-title":"Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial","volume":"357","author":"Smilde","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib82","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvistatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib83","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/01.CIR.102.16.1893","article-title":"Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project","volume":"102","author":"Sacks","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib84","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib85","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Cannon","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib86","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/01.CIR.101.5.477","article-title":"Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TexCAPS)","volume":"101","author":"Gotto","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib87","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib88","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(95)90926-5","article-title":"Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib89","unstructured":"http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00120289?order=1"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib90","unstructured":"http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00000620?order=4"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib91","unstructured":"Zetia (ezetimibe) package insert. Kenilworth, NJ: Schering Corporation, 2002."},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib92","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib93","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2165\/00003495-200262160-00002","article-title":"Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia","volume":"62","author":"Sudhop","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib94","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib95","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazoladinedione is a high affinity ligand for peroxisome proliferators-activated receptor-gamma (PPAR-gamma)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib96","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1006\/bbrc.2000.3868","article-title":"Activation of human peroxisome proliferators-activated receptor (PPAR) subtypes by pioglitazone","volume":"278","author":"Sakamoto","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib97","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1172\/JCI200523219","article-title":"Effects of the PPAR-\u03b3 agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus","volume":"115","author":"Nagashima","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib98","doi-asserted-by":"crossref","unstructured":"Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351;11:1106-18.","DOI":"10.1056\/NEJMra041001"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib99","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1161\/01.ATV.0000195790.24531.4f","article-title":"Effects of pioglitazone on lipoproteins, inflammatory markers and adipokines in nondiabetic patients with metabolic syndrome","volume":"26","author":"Szapary","year":"2006","journal-title":"Atherioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib100","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type two diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial I macrovascular Events): a randomized control trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib101","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","article-title":"A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia","volume":"28","author":"Goldberg","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib102","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/meta.2003.50100","article-title":"Differential effects of peroxisome proliferator-activated receptor activators of the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages","volume":"52","author":"Cabrero","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib103","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.2337\/diacare.26.9.2588","article-title":"Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study","volume":"26","author":"Winkler","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib104","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00125-004-1485-5","article-title":"Rationale, design and recruitment of a large, simple, international trial of diabetes prevention: the DREAM trial","volume":"47","author":"Gerstein","year":"2004","journal-title":"Diabetologica"},{"issue":"6","key":"10.1016\/j.cpcardiol.2007.01.004_bib105","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.2337\/diacare.27.6.1324","article-title":"Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects","volume":"27","author":"Saad","year":"2004","journal-title":"Diabetes Care"},{"issue":"20","key":"10.1016\/j.cpcardiol.2007.01.004_bib106","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.294.20.joc50147","article-title":"Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus","volume":"294","author":"Nissen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib107","doi-asserted-by":"crossref","first-page":"15277","DOI":"10.1016\/S0021-9258(17)42546-4","article-title":"Estradiol-induced alteration of very-low-density lipoprotein assembly","volume":"259","author":"Miller","year":"1984","journal-title":"J Boil Chem"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib108","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJM199110243251702","article-title":"Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins","volume":"325","author":"Walsh","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib109","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the ris of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib110","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1210\/jc.80.11.3191","article-title":"The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women","author":"Grey","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib111","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of Raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib112","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1172\/JCI118345","article-title":"Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response","volume":"96","author":"Van Lenten","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib113","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of Rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib114","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib115","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib116","first-page":"780","article-title":"Relationship of the phenotypic expression of apo-A-I Milano apoprotein with plasma lipid and lipoprotein patterns","volume":"97","author":"Franceschini","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib117","first-page":"1083","article-title":"Identification of the complete kindred and evidence of a dominant genetic transmission","volume":"37","author":"Gualandri","year":"1985","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib118","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1161\/01.CIR.103.15.1949","article-title":"Cardiovascular status of carriers of the apolipoprotein A-I (Milano) mutant: the Limone sul Garda Study","volume":"103","author":"Sirtori","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib119","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1161\/01.ATV.19.5.1257","article-title":"Increased cholesterol efflux potential of sera from apo-A-I Milano carriers and transgenic mice","volume":"19","author":"Franceschini","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib120","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1161\/hc2501.092494","article-title":"High dose recombinant apo-A-I Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein-e deficient mice","volume":"103","author":"Shah","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib121","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib122","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/00041433-200412000-00004","article-title":"Human apolipoprotein A-I and A-I mimetic peptides:potential for atherosclerosis reversal","volume":"15","author":"Navab","year":"2004","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib123","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/342448a0","article-title":"Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins","volume":"342","author":"Brown","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib124","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1161\/01.ATV.20.5.1323","article-title":"Association of cholesteryl ester transfer protein-TaqB1 polymorphism with variations in lipoprotein subclasses and coronary heart disease ris:the Framingham study","volume":"20","author":"Ordovas","year":"2000","journal-title":"Arteriosclerosis Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/35018119","article-title":"A cholesteryl ester transfer protein attenuates atherosclerosis in rabbits","volume":"406","author":"Okamato","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib126","unstructured":"Morehouse LA. The CETP-inhibitor Torctrapib raises HDL and prevents aortic atherosclerosis in rabbits. Presented at XV International Symposium on Drugs Affecting Lipid Metabolism, October 24 to 27, 2004, Venice, Italy."},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib127","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/01.ATV.20.9.2106","article-title":"Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model or atherosclerosis","volume":"20","author":"Rittershaus","year":"2000","journal-title":"Ateriosclerosis Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib128","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1042\/cs1030587","article-title":"Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia","volume":"103","author":"Huang","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib129","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1172\/JCI118751","article-title":"Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels","volume":"97","author":"Zhong","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2362.2004.01281.x","article-title":"Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS)","volume":"34","author":"Klerkx","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib131","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1161\/01.CIR.0000141730.65972.95","article-title":"Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women:the prospective EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk population study","volume":"110","author":"Boekholdt","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib132","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.atherosclerosis.2003.11.020","article-title":"The relationship between cholesteryl ester transfer protein levels and risk profile in patients with familial hypercholesterolemia","volume":"173","author":"De Grooth","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib133","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0021-9150(03)00137-0","article-title":"The safety and immunogenicity of a CETP vaccine in healthy adults","volume":"169","author":"Davidson","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib134","doi-asserted-by":"crossref","unstructured":"De Grooth GJ. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105:2159-65.","DOI":"10.1161\/01.CIR.0000015857.31889.7B"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib135","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.amjcard.2004.12.064","article-title":"Inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia","volume":"95","author":"Kuivenhoven","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib136","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1161\/01.ATV.0000179009.60612.28","article-title":"Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia","volume":"25","author":"Bisoendial","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib137","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.ATV.0000118278.21719.17","article-title":"Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib","volume":"24","author":"Clark","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib138","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMoa031766","article-title":"Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol","volume":"350","author":"Brousseau","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib139","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1194\/jlr.M500349-JLR200","article-title":"Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action","volume":"47","author":"Clark","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib140","unstructured":"Davison M. Efficacy and safety of a novel CETP inhibitor torcetrapib administered with and without atorvastatin in subjects with a low level of HDL-C. Am Coll Cardiol Scientific Session 2005 March 6-9 2005, Orlando, FL."},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib141","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1161\/01.ATV.0000161928.16334.dd","article-title":"Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion","volume":"25","author":"Brousseau","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cpcardiol.2007.01.004_bib142","first-page":"3142","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults. (Adult Treatment Panel III). Final Report","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"suppl 1","key":"10.1016\/j.cpcardiol.2007.01.004_bib143","first-page":"S68","article-title":"American Diabetes Association Position Statement.","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.cpcardiol.2007.01.004_bib144","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000114834.85476.81","article-title":"Evidence-based guidelines for cardiovascular disease prevention in women","volume":"109","author":"Mosca","year":"2004","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.cpcardiol.2007.01.004_bib145","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/archinte.159.10.1049","article-title":"New perspectives on the management of low levels of high-density lipoprotein cholesterol","volume":"159","author":"Harper","year":"1999","journal-title":"Arch Intern Med"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280607000059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280607000059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T05:12:03Z","timestamp":1628831523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280607000059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":145,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0146280607000059"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2007.01.004","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}